Microbiome Therapeutic Beats Placebo for Recurrent C. difficile
Investigational oral live microbiome therapeutic superior to placebo in patients with three or more episodes of C. difficile infection
Gastrohepatic Disorders
Biosimilars Could Cut Spending for Biologic Therapy in the US
Increased market growth of biosimilars that are similar to brand-name biologic agents has the potential to reduce spending on prescription drugs
ACP Issues 2 Guidelines for Acute Left-Sided Colonic Diverticulitis
Guidelines address diagnosis and management, use of diagnostic colonoscopy in complicated disease, and interventions to prevent recurrence
Two Doses of BNT162b2 Vaccine Protect Against MIS-C
Two doses of Pfizer-BioNTech vaccine have estimated effectiveness of 91 percent against MIS-C in children aged 12 to 18 years
Factors ID’d for Severe GI Effects of SARS-CoV-2 in Children
Among children infected with SARS-CoV-2, 9.5 percent have severe GI effects, such as disseminated adenomesenteritis, appendicitis, pancreatitis
Clinical Remission, Endoscopic Response Seen With Upadacitinib in Crohn Disease Trial
Over 60% of the study participants had previously failed 2 or more biologic therapies.
Cyclophilin Inhibitor Fast Tracked for Nonalcoholic Steatohepatitis
In preclinical studies, CRV431 has been shown to reduce liver fibrosis and hepatocellular tumor burden.
Kraft Recalls Powdered Drinks Over Metal, Glass Concerns
The problem with the glass and metal pieces occurred during production.
NDA Submitted for Aprepitant 30-Second IV Injection for Postoperative Nausea, Vomiting
HTX-019 is a proprietary IV injectable emulsion formulation designed to directly deliver aprepitant, a substance P/NK1 receptor antagonist, as a 30-second IV injection.
MPR Weekly Dose Podcast Episode 100
This week Pfizer seeks Emergency Use Authorization for their COVID-19 oral antiviral; A meta-analysis found commonly prescribed drugs were linked to orthostatic hypotension; A novel treatment is approved for polycythemia vera; A new program has been cleared to allow individuals to carry out remote endoscopy procedures; And the largest to date psilocybin trial shows promise in treatment-resistant depression.
